Nature Communications publication reveals highly efficient AAV delivery of large genes using ViGeneron´s REVeRT technology
REVeRT, a dual vector approach based on mRNA trans-splicing, enables delivery of genes larger than the usual AAV packagi…
REVeRT, a dual vector approach based on mRNA trans-splicing, enables delivery of genes larger than the usual AAV packagi…
ViGeneron GmbH (ViGeneron), a next-generation gene therapy company, today announced that the European Medicines Agency (…
ViGeneron GmbH, a next-generation gene therapy company, today announced a follow-on collaboration with Daiichi Sankyo Co…
Regeneron receives access to ViGeneron’s vgAAV capsids for one inherited retinal disease target and an option for an exc…
Efficient transfer of larger gene via ViGeneron’s proprietary technology platforms REVeRT and vgAAV ViGeneron advances i…
ViGeneron GmbH, a gene therapy company, today announced a research collaboration to utilize its novel engineered adeno-a…
. - Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus op…
Funds will advance development of ViGeneron’s next-generation ophthalmic gene therapy pipeline and vector platforms Roun…